57229-37-5

Usage

InChI:InChI=1/C7H7N3O3/c11-6(12)4-10-7(13)5-3-8-1-2-9-5/h1-3H,4H2,(H,10,13)(H,11,12)

Upstream product

• 19847-10-0 pyrazinoyl chloride 
• 56-40-6 glycine 
• 117904-01-5 (N-(methoxycarbonylmethyl)-carboxamido)-pyrazine 
• 7364-42-3 N,O-bis(trimethylsilyl)glycine 
• 103435-88-7 pyrazinecarboxylic acid imidazolide 
• 98-97-5 2-pyrazylcarboxylic acid 
• 306990-94-3 (1H-benzo[d][1,2,3]triazol-1-yl)(pyrazin-2-yl)methanone 
• 6164-79-0 methyl pyrazine-2-carboxylate 

Relevant academic research and scientific papers

Syntheses of some N-(pyrazinecarbonyl)amino acids and peptides

Derivatives of some amino acids, having a pyrazinecarbonyl or 3-aminopyrazinecabonyl radical, have been synthesized and some peptides prepared.In the case of the 3-aminopyrazinecarbonyl derivatives, condensed pyrimidines, i.e. 4(3H)-pteridinone derivatives, could be prepared.

New Pyrazine Conjugates: Synthesis, Computational Studies, and Antiviral Properties against SARS-CoV-2

Currently, limited therapeutic options are available for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We have developed a set of pyrazine-based small molecules. A series of pyrazine conjugates was synthesized by microwave-assisted click chemistry and benzotriazole chemistry. All the synthesized conjugates were screened against the SAR-CoV-2 virus and their cytotoxicity was determined. Computational studies were carried out to validate the biological data. Some of the pyrazine-triazole conjugates (5 d–g) and (S)-N-(1-(benzo[d]thiazol-2-yl)-2-phenylethyl)pyrazine-2-carboxamide 12 i show significant potency against SARS-CoV-2 among the synthesized conjugates. The selectivity index (SI) of potent conjugates indicates significant efficacy compared to the reference drug (Favipiravir).

N-Pyrazinoyl substituted amino acids as potential antimycobacterial agents-the synthesis and biological evaluation of enantiomers

Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis (Mtb), each year causing millions of deaths. In this article, we present the synthesis and biological evaluations of new potential antimycobacterial compounds containing a fragment of the first-line antitubercular drug pyrazinamide (PZA), coupled with methyl or ethyl esters of selected amino acids. The antimicrobial activity was evaluated on a variety of (myco)bacterial strains, including Mtb H37Ra, M. smegmatis, M. aurum, Staphylococcus aureus, Pseudomonas aeruginosa, and fungal strains, including Candida albicans and Aspergillus flavus. Emphasis was placed on the comparison of enantiomer activities. None of the synthesized compounds showed any significant activity against fungal strains, and their antibacterial activities were also low, the best minimum inhibitory concentration (MIC) value was 31.25 μM. However, several compounds presented high activity against Mtb. Overall, higher activity was seen in derivatives containing l-amino acids. Similarly, the activity seems tied to the more lipophilic compounds. The most active derivative contained phenylglycine moiety (PC-d/l-Pgl-Me, MIC 1.95 μg/mL). All active compounds possessed low cytotoxicity and good selectivity towards Mtb. To the best of our knowledge, this is the first study comparing the activities of the d- and l-amino acid derivatives of pyrazinamide as potential antimycobacterial compounds.

Fluoroquinolone such amino derivative and use thereof (by machine translation)

The invention belongs to the field of pharmaceutical chemistry, and in particular relates to a fluoroquinolone derivatives and use thereof. The invention through structural modification of the fluoroquinolone drugs such as shown in formula I, the compounds of the invention not only can the Mycobacterium tuberculosis and the normal bacterial caused by the treatment of infection, bacteria also holds keeps the fungus, citrus pathogens, nicotinamide N - methyltransferase (NNMT) and interleukin IL - 17 PPI has inhibitory activity. The compounds of the invention preparation process operation is convenient, mild condition, to obtain the antibacterial activity is enhanced, water-soluble improve, many compounds toxic side effects, it is expected to reduce the amount of medicine used, shorten the treatment cycle, improve patient's compliance, for tuberculosis drug and other disease research provide new molecular type with the study. (by machine translation)

Bortezomib congeners induce apoptosis of hepatocellular carcinoma via CIP2A inhibition

CIP2A is an oncoprotein that upregulates p-Akt and promotes cancer cell proliferation and survival. The proteasome inhibitor bortezomib has been shown to reduce CIP2A and lead to cell apoptosis. Here; we modified the functional group of bortezomib to generate a series of novel compounds and conducted a structure-activity relationship (SAR) study. The results showed that compound 1 was able to repress CIP2A expression and cell apoptosis in the same manner as bortezomib, but with less potency in inhibition of proteasome activity. This finding provides a new direction for the design of CIP2A inhibitors.

Chemical and biological evaluation of dipeptidyl boronic acid proteasome inhibitors for use in prodrugs and pro-soft drugs targeting solid tumors

Bortezomib, a dipeptidyl boronic acid and potent inhibitor of the 26S proteasome, is remarkably effective against multiple myeloma (MM) but not against solid tumors. Dose-limiting adverse effects from "on target" inhibition of the proteasome in normal cells and tissues appear to be a key obstacle. Achieving efficacy against solid tumors therefore is likely to require making the inhibitor more selective for tumor tissue over normal tissues. The simplest strategy that might provide such tissue specificity would be to employ a tumor specific protease to release an inhibitor from a larger, noninhibitory structure. However, such release would necessarily generate an inhibitor with a free N-terminal amino group, raising a key question: Can short peptide boronic acids with N-terminal amino groups have the requisite properties to serve as warheads in prodrugs? Here we show that dipeptides of boroLeu, the smallest plausible candidates for the task, can indeed be sufficiently potent, cell-penetrating, cytotoxic, and stable to degradation by cellular peptidases to serve in this capacity.